Asian Growth Companies With Insider Ownership August 2026

As the Asian markets navigate a complex landscape of geopolitical developments and economic fluctuations, investor focus has increasingly turned toward growth companies with significant insider ownership. In this environment, stocks that combine robust growth potential with high levels of insider investment can offer an intriguing proposition for those seeking to align their interests with company leadership.

Top 10 Growth Companies With High Insider Ownership In Asia

Name	Insider Ownership	Earnings Growth
Zhejiang Taotao Vehicles (SZSE:301345)	27.9%	31.5%
Shanghai Biren Technology (SEHK:6082)	11%	116.9%
Meiko Electronics (TSE:6787)	19.2%	30.1%
Jiangxi Fushine Pharmaceutical (SZSE:300497)	21.1%	50.8%
Guangzhou Tinci Materials Technology (SZSE:002709)	38.4%	28.3%
Gpixel Changchun Microelectronics (SEHK:3277)	18.2%	34.2%
Gold Circuit Electronics (TWSE:2368)	30.1%	43.4%
Fulin Precision (SZSE:300432)	10.4%	60.7%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	14.1%	41%
ASE Technology Holding (TWSE:3711)	25.7%	37.5%

Click here to see the full list of 492 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Metis TechBio (SEHK:7666)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Metis TechBio Co., Ltd. focuses on the research and development of AI-empowered nanomaterials for delivering active agents across carbon-based life forms in Chinese Mainland and the United States, with a market cap of HK$14.93 billion.

Operations: The company's revenue segment is primarily from the research and development of new nano materials, totaling CN¥105 million.

Insider Ownership: 23.2%

Revenue Growth Forecast: 29.9% p.a.

Metis TechBio is poised for significant growth, with revenue projected to increase by 29.9% annually, outpacing the Hong Kong market. Despite high insider ownership and innovative AI-driven platforms like NanoForge and AiTEM enhancing drug formulation efficiency, its Return on Equity forecast remains low at 4.9%. Recent executive changes and collaborations signal strategic shifts aimed at leveraging their proprietary technologies for expanded commercial applications, such as a US$1.6 billion milestone agreement with Boulevard Bio Inc.

• Click here to discover the nuances of Metis TechBio with our detailed analytical future growth report.
• Upon reviewing our latest valuation report, Metis TechBio's share price might be too optimistic.

Nanjing Vazyme Biotech (SHSE:688105)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics with a market cap of CN¥12.20 billion.

Operations: The company's revenue segments include technology solutions for life science, biomedicine, and in vitro diagnostics.

Insider Ownership: 14.9%

Revenue Growth Forecast: 17.2% p.a.

Nanjing Vazyme Biotech is positioned for growth, with revenue expected to rise by 17.2% annually, slightly surpassing the Chinese market average. Despite a volatile share price and a low forecasted Return on Equity of 4.5%, the company anticipates becoming profitable within three years, indicating robust earnings growth of 65.51% per year. Recent events include the closure of a buyback plan and an extraordinary shareholders meeting in June 2026.

• Get an in-depth perspective on Nanjing Vazyme Biotech's performance by reading our analyst estimates report here.
• In light of our recent valuation report, it seems possible that Nanjing Vazyme Biotech is trading beyond its estimated value.

Yangtze Optical Electronic (SHSE:688143)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Yangtze Optical Electronic Co., Ltd. focuses on the R&D, production, and sale of special optical fibers and cables, optical devices, new materials, high-end equipment, and photoelectric systems in China with a market cap of CN¥14.94 billion.

Operations: Yangtze Optical Electronic Co., Ltd. generates revenue from its Optoelectronics Manufacturing segment, amounting to CN¥417.31 million.

Insider Ownership: 24.4%

Revenue Growth Forecast: 28.0% p.a.

Yangtze Optical Electronic is poised for substantial growth, with earnings projected to rise by 56.76% annually, significantly outpacing the broader Chinese market. Revenue is also expected to grow at a robust 28% per year. Despite recent share price volatility and low forecasted Return on Equity of 12.1%, the company's growth prospects remain strong. Recent earnings calls in May and July 2026 have provided further insights into its financial trajectory, though insider trading activity remains minimal over the past three months.

• Click to explore a detailed breakdown of our findings in Yangtze Optical Electronic's earnings growth report.
• The valuation report we've compiled suggests that Yangtze Optical Electronic's current price could be inflated.

Seize The Opportunity

• Click through to start exploring the rest of the 489 Fast Growing Asian Companies With High Insider Ownership now.
• Ready To Venture Into Other Investment Styles? AI is about to change healthcare. These 130 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com